内容摘要：is made by fermenting a mixture of soybeans and roasted wheat in salt and water, and straining out the solids so that only a liquid remains.

is made by fermenting a mixture of soybeans and roasted wheat in salt and water, and straining out the solids so that only a liquid remains.

from Montce at Casa Faena, now’s the perfect time to try out which pastel shade is best for you.At this year’s Couture Jewelry Show in Las Vegas, the designs were teeming with originality and innovation. There were takes on classics and classic materials reimagined. Of the hundreds of thousands of pieces on display during the four-day-long event, here are the ten trends that really stood out to ELLE's Fashion & Market Accessories Director.

JoEllen Zembruski-Ruple, while in the care of New York City’s renowned Memorial Sloan Kettering Cancer Center, swallowed the first three chemotherapy pills to treat her squamous cell carcinoma on Jan. 29, her family members said. They didn’t realize the drug could kill her.Six days later, Zembruski-Ruple went to Sloan Kettering’s urgent care department to treat sores in her mouth and swelling around her eyes. The hospital diagnosed oral yeast infection and sent her home, her sister and partner said. Two days later, they said, she returned in agony — with severe diarrhea and vomiting — and was admitted. “Enzyme deficiency,” Zembruski-Ruple texted a friend.The 65-year-old, a patient advocate who had worked for the National Multiple Sclerosis Society and other groups, would never go home.

Covered in bruises and unable to swallow or talk, she eventually entered hospice care andfrom the very drug that was supposed to extend her life, said her longtime partner, Richard Khavkine. Zembruski-Ruple was deficient in the enzyme that metabolizes capecitabine, the chemotherapy drug she took, said Khavkine and Susan Zembruski, one of her sisters. Zembruski-Ruple was among

or its cousin, the IV drug fluorouracil known as 5-FU.

if patients have a genetic variant that carries risk. The FDASemaglutide belongs to a class of drugs known as GLP-1 receptor agonists. These were originally designed to treat type 2 diabetes. But over time, doctors noticed that many patients lost weight while taking the medication. This led to the approval of semaglutide for treating obesity under brand names like Ozempic and Wegovy.

In large clinical trials, people taking semaglutide lost about 15% of their body weight over 68 weeks. That’s more than most other weight-loss drugs on the market. Yet many patients experience side effects, including nausea. And some studies have raised concerns about the drug reducing lean muscle mass, which could become a problem for older adults.Scientists already knew that semaglutide lowers blood sugar by acting directly on the pancreas. But when it comes to weight loss, the brain plays the main role. Even though

doesn’t easily cross the blood-brain barrier, it collects in certain brain regions that don’t have one—especially an area called the dorsal vagal complex, or DVC.This part of the brainstem includes two key areas: the area postrema and the nucleus of the solitary tract. Both are known to influence appetite, digestion, and metabolism. When semaglutide reaches this region, it activates brain cells that reduce hunger and body weight. But the details of that process have remained unclear—until now.